Literature DB >> 32026762

Association Between Extent of Stent-Graft Coverage and Thoracic Aortic Remodeling After Endovascular Repair of Type B Aortic Dissection.

Yan Xue1,2, Yangyang Ge1,2, Xiaohu Ge3, Jianhang Miao4, Weidong Fan5, Dan Rong1,2, Feng Liu1,2, Xiaoping Liu1,2, Wei Guo1,2.   

Abstract

Purpose: To examine the association between the extent of stent-graft coverage and thoracic aortic expansion after thoracic endovascular aortic repair (TEVAR) for type B aortic dissection. Materials and
Methods: A retrospective analysis was conducted of 201 patients (mean age 52.4±11.5 years; 178 men) with acute (135, 67.2%) or chronic (66, 32.8%) type B aortic dissection who underwent TEVAR at 4 medical centers. The mean stent-graft length was 157.1±33.3 mm. The percentage of stented descending aorta (PSDA) represented the extent of stent-graft coverage. After using restricted cubic smoothing spline plots to confirm the roughly linear relationship between PSDA and the risk of thoracic aortic expansion, patients were stratified into 2 groups on the median PSDA: the lower group (≤31.3%) and the higher group (>31.3%). Thoracic aortic expansion was defined as a ≥20% increase in the total thoracic aortic volume on the most recent postoperative computed tomography angiography scan compared with the preoperative measurement. The Kaplan-Meier method was used to estimate the cumulative freedom from thoracic aortic expansion after TEVAR; estimates are given with the 95% confidence interval (CI). A multivariable Cox proportional hazards model was used to analyze any independent association of the PSDA as a continuous or categorical variable with the risk of thoracic aortic expansion; results are presented as the hazard ratio (HR) and 95% CI.
Results: No patients developed symptoms of spinal cord ischemia during hospitalization. Over a median 12.4 months of imaging follow-up, 34 (16.9%) patients developed thoracic aortic expansion. The estimate of freedom from thoracic aortic expansion at 12 months for the overall PSDA was 84.0% (95% CI 77.8% to 88.6%); between the groups, the freedom from thoracic aortic expansion estimate for the PSDA ≤31.3% group was significantly lower than in the higher group (p=0.032). Regression analysis showed no significant association between the risk of thoracic aortic expansion and the PSDA as a continuous variable (HR 0.97, 95% CI 0.91 to 1.03, p=0.288); however, analyzing the PSDA as a categorical variable indicated a significantly lower risk of thoracic aortic expansion for the PSDA >31.3% group (HR 0.46, 95% CI 0.22 to 0.95, p=0.036) after adjusting for a variety of demographic and anatomical characteristics.
Conclusion: More extensive stent-graft coverage appears to improve thoracic aortic remodeling after TEVAR. However, the clinician should balance the benefit of extensive stent-graft coverage and its related risk of spinal cord ischemia.

Entities:  

Keywords:  aortic coverage; aortic dissection; aortic remodeling; endograft; false lumen; spinal cord ischemia; stent-graft; thoracic aortic expansion; thoracic endovascular aortic repair; type B aortic dissection

Mesh:

Year:  2020        PMID: 32026762     DOI: 10.1177/1526602820904164

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  3 in total

Review 1.  Complicated acute type B aortic dissection: update on management and results.

Authors:  Eric Y Pruitt; Salvatore T Scali; Dean J Arnaoutakis; Martin R Back; George J Arnaoutakis; Tomas D Martin; Thomas M Beaver; Thomas S Huber; Gilbert R Upchurch
Journal:  J Cardiovasc Surg (Torino)       Date:  2020-09-23       Impact factor: 1.888

2.  Association between aortic coverage and spinal cord ischemia after endovascular repair of type B aortic dissection.

Authors:  Mansi Verma; Vineeta Ojha; Amit Ajit Deshpande; Surya Pratap Singh; Pradeep Ramakrishnan; Sanjeev Kumar
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2022-05-11

Review 3.  Role of Endoluminal Techniques in the Management of Chronic Type B Aortic Dissection.

Authors:  Konstantinos Spanos; Tilo Kölbel
Journal:  Cardiovasc Intervent Radiol       Date:  2020-06-29       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.